G
Greg Fulcher
Researcher at Royal North Shore Hospital
Publications - 92
Citations - 14608
Greg Fulcher is an academic researcher from Royal North Shore Hospital. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 31, co-authored 85 publications receiving 12461 citations. Previous affiliations of Greg Fulcher include University of Sydney & Royal Prince Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
Andrew Tonkin,P. Alyward,David Colquhoun,Paul Glasziou,P. Harris,D. Hunt,Anthony C Keech,Stephen MacMahon,P. Magnus,D. Newel,P. Nestel,N. Sharpe,J. Shaw,R. J. Simes,P. Thompson,Alexis A. Thompson,Malcolm J. West,H. White,S. Simes,Wendy Hague,Sue Caleo,Jane Hall,Andrew J. Martin,S. Mulray,Philip J. Barter,Lawrence J. Beilin,Rory Collins,John J McNeil,Petra Meier,H. Willimott,D. Smithers,P. Wallace,J. Baker,M. Hobbs,David R. Sullivan,N. Anderson,Graeme J. Hankey,John D.G. Watson,M. Arulchelvam,S. Chup,John Daly,J. Hanna,A. Leach,M. Lee,J. Loughhead,H. Lundie-Jenkin,J. Morrison,S. Netting,A. Nguyen,H. Pater,R. Philip,G. Pinna,D. Rattos,S. Ryerson,V. Sazhin,Richard Walsh,A. Claque,M. Mackie,Julie Jane Yallop,K. Boss,M. Shepard,J. Leach,M. Gandy,J. Joughin,J. Seabrook,R. Abraham,J. Allen,F. Bates,I. Beinart,E. Breed,D. Brown,N. Bunyan,D. Calvert,T. Campbell,D. Condon-Paoloni,B. Conway,Lucy A. Coupland,J. Crowe,N. Cunio,B. Cuthbert,N. Cuthbert,S. D'Arcy,Patricia M. Davidson,B. Dwyer,J. England,C. Friend,Greg Fulcher,S. Grant,K. Hellestrand,M. Kava,Leonard Kritharides,D. McGill,H. McKee,Allan J. McLean,M. Neaverson,G. Nelson,M. O'Neill,C. Onuma,F. O'Reilly +98 more
TL;DR: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Journal ArticleDOI
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Bruce Neal,Vlado Perkovic,Vlado Perkovic,Kenneth W. Mahaffey,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Gordon Law,Mehul Desai,David R. Matthews +10 more
TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Journal ArticleDOI
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Russell S. Scott,Richard C O'Brien,Greg Fulcher,Chris Pardy,Michael C d'Emden,Dana Tse,Marja-Riitta Taskinen,Christian Ehnholm,Anthony C Keech +8 more
TL;DR: Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present.
Journal ArticleDOI
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic,Vlado Perkovic,Dick de Zeeuw,Kenneth W. Mahaffey,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Terrance D. Barrett,Michele A. Weidner-Wells,Hsiaowei Deng,David R. Matthews,Bruce Neal +11 more
TL;DR: Canagliflozin treatment was associated with a reduced risk of sustained loss of kidney function, attenuated eGFR decline, and a reduction in albuminuria in patients with type 2 diabetes.
Journal ArticleDOI
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W. Mahaffey,Bruce Neal,Vlado Perkovic,Dick de Zeeuw,Greg Fulcher,Ngozi Erondu,Wayne Shaw,Elisa Fabbrini,Tao Sun,Qiang Li,Mehul Desai,David R. Matthews +11 more
TL;DR: Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups.